References
- Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419–27
- Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized con-trolled trial. Climacteric 2003;6:302–10
- Shapiro S. Bias in the evaluation of low-magnitude associations: an empirical perspective. Am J Epidemiol 2000;151:939–1000
- Calvin FU, Mello-Thoms C, Kandel HL, Weinstein SP. Course and perception of decision making during mammographic interpretation. Am J Roentgenol 2002;179:917–23
- Greendale GA, Reboussin BA, Sie A, etal. Effects of estrogen-progestin on mammographic paren-chymal density. Ann Intern Med 1999;130: 262–9
- Banks E, Beral V, Cameron R, et al. Comparison of various characteristics of women who do and do not attend for breast cancer screening. Breast Cancer Research 2001;http://breast-cancer-research.com/content/4/1/R1
- Morrison AS, Brisson J, Khalid N. Breast cancer incidence and mortality in the Breast Cancer Detection Demonstration Project. J Natl Cancer Inst 1988;80:1540–7
- MacLennan AH. Cancer, cohorts and consensus. Climacteric 1998;1:89–91
- Garton M. Breast cancer and hormone-replace-ment therapy: the Million Women Study (Letter). Lancet 2002;362:1328
- Bliss JM, Gray R. Breast cancer and hormone-replacement therapy: the Million Women Study (Letter). Lancet 2002;362:1328–9
- Bundred NJ, Morris J. Breast cancer and hormone-replacement therapy: the Million Women Study (Letter). Lancet 2002;362:1329
- Helmond FA. Breast cancer and hormone-replacement therapy: the Million Women Study (Letter). Lancet 2002;362:1330
- Van Leeuwen FE, Rookus MA. Breast cancer and hormone-replacement therapy: the Million Women Study (Letter). Lancet 2002; 362:1330
- Beral V, Banks E, Reeves G, Bull D. Breast cancer and hormone replacement therapy: the Million Women Study (Letter). Lancet 2002; 362:1330–1
- Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1977;350: 1047–59
- Writing Group for the Women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initia-tive randomized controlled trial. J Am Med Assoc 2002;288:321–33
- Shapiro S. Effects of HRT on the risks of cancer and cardiovascular disease. The validity of the epidemiological evidence. Proceedings of the Fourth Workshop of the International Meno-pause Society. Climacteric Medicine: Where Do We Go? London: Parthenon Publishing, 2004: in press